Bruce Cree, MD, PhD, MAS, FAAN
Professor of clinical neurology, and George A. Zimmermann Endowed Professor in Multiple Sclerosis, Department of Neurology, University of California San Francisco
Articles
Overviewing the N-MOmentum Trial of Inebilizumab for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
June 11th 2024The clinical research director of the UCSF Multiple Sclerosis Center provided an overview of the phase 2/3 N-Momentum study assessing the efficacy of inebilizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]
Challenges and Potential of BTK Inhibitors in MS Treatment: Bruce Cree, MD, PhD, MAS, FAAN
May 30th 2024The clinical research director of the UCSF Multiple Sclerosis Center talked about results from clinical trials assessing BTK inhibitors in relapsing multiple sclerosis and the ongoing research to explore more effective treatments. [WATCH TIME: 5 minutes]
Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN
May 29th 2024The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]
The Payor Dilemma With Accessing Effective Therapies for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
November 4th 2023The clinical research director of the UCSF Multiple Sclerosis Center talked about challenges in accessibility for the 3 approved therapies for NMOSD caused by third-party payor resistance as well as the importance of educating clinicians about the effectiveness of inebilizumab. [WATCH TIME: 3 minutes]
Long-Term Benefits of Inebilizumab Revealed in N-MOmentum Analysis: Bruce Cree, MD, PhD, MAS, FAAN
October 13th 2023The clinical research director of the UCSF Multiple Sclerosis Center talked about a clinical trial highlighting the therapeutic benefits of longterm treatment with inebilizumab in patients with NMOSD. [WATCH TIME: 4 minutes]
Emerging Disease-Modifying Therapy Data in Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, discusses new data presented at the 2023 European Academy of Neurology (EAN) congress on BTK inhibitors, such as Tolebrutinib, evobrutinib, renibrutinib, and fenibrutinib. Dr Cree also highlights important safety information and adverse events identified in these studies.
Long-term Data With Ozanimod in Relapsing-Remitting Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, reviews the results of the long-term efficacy and safety study of ozanimod, DAYBREAK, in relapsing-remitting multiple sclerosis (RRMS) published last year. Dr Cree also discusses two other safety studies presented at the 2023 European Academy of Neurology (EAN) congress.
Selecting S1P Receptor Modulators in Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, discusses key considerations when selecting one of the four FDA approved sphinogine-1-phospate (S1P) receptor modulators for multiple sclerosis (MS). Dr Cree also highlights a particular adverse event observed in the extension studies of these four S1P receptor modulators.
S1P Receptor Modulators in Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, discusses the pathophysiology of multiple sclerosis (MS) and how sphinogine-1-phospate (S1P) receptor modulators address the underlying causes. Dr Cree also discusses the differences between the four FDA approved drugs for MS: fingolimod, siponimod, ozanimod, and ponesimod.
Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAAN
November 3rd 2022The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]
Ublixtumab’s Effect on Measures of MS Disability: Bruce Cree, MD, PhD, MAS, FAAN
April 17th 2022The clinical research director of the UCSF Multiple Sclerosis Center discussed the recently presented analysis on ublituximab’s effect on disability in relapsing MS and the critical need to focus on improving quality of life. [WATCH TIME: 4 minutes]
The Therapeutic Advances in Efficacy for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
April 7th 2022The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]
New Sponsors, Potential Development in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
October 24th 2021Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]
Patient Education and Awareness in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
October 13th 2021The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]
Day-to-Day Care of NMOSD, Advances and Challenges: Bruce Cree, MD, PhD, MAS, FAAN
October 12th 2021Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]
Recent Advances and New Therapies for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
October 11th 2021The clinical research director of the UCSF Multiple Sclerosis Center provided an overview on the state of care for NMOSD, specifically the development of inebilizumab, satralizumab, and eculizumab. [WATCH TIME: 6 minutes]
